KRAS and colonic neoplasm: Having established the anti-tumor efficacy of the cetuximab/NK cell combination with the EGFR+++ cell line A431, our next aim was to extend these findings to colon cancer cell lines COLO320 (EGFR-, RASwt), SW480 (EGFR+ RASmut; KRAS exon 2 c.35>T; p.G12V), SW620 (EGFR+ RASmut; KRAS exon 2 c.35>T; p.G12V) and HT-29 (EGFR+, RASwt, BRAFmut).